Schwab Charles Investment Management Inc. lessened its stake in shares of MiMedx Group Inc (NASDAQ:MDXG) by 1.3% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 609,168 shares of the medical equipment provider’s stock after selling 7,974 shares during the period. Schwab Charles Investment Management Inc.’s holdings in MiMedx Group were worth $4,246,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of MDXG. BlueCrest Capital Management Ltd bought a new position in MiMedx Group in the 4th quarter valued at $126,000. First Republic Investment Management Inc. bought a new position in MiMedx Group in the 4th quarter valued at $153,000. Xact Kapitalforvaltning AB bought a new position in MiMedx Group in the 4th quarter valued at $182,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new position in MiMedx Group in the 4th quarter valued at $231,000. Finally, Virginia Retirement Systems ET AL bought a new position in MiMedx Group in the 1st quarter valued at $257,000. Institutional investors and hedge funds own 75.30% of the company’s stock.
Shares of MiMedx Group opened at $6.25 on Wednesday, according to MarketBeat.com. MiMedx Group Inc has a 52-week low of $4.95 and a 52-week high of $18.25. The firm has a market capitalization of $647.33 million, a price-to-earnings ratio of 27.76, a price-to-earnings-growth ratio of 0.76 and a beta of 1.53.
Several equities analysts have issued reports on MDXG shares. ValuEngine downgraded MiMedx Group from a “sell” rating to a “strong sell” rating in a research report on Wednesday, May 2nd. BidaskClub downgraded MiMedx Group from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 16th. Craig Hallum reiterated a “buy” rating on shares of MiMedx Group in a research report on Tuesday, February 27th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of MiMedx Group in a research report on Thursday, March 15th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. MiMedx Group has a consensus rating of “Hold” and a consensus target price of $16.00.
About MiMedx Group
MiMedx Group, Inc, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.
Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group Inc (NASDAQ:MDXG).
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.